Skip to main content

Advertisement

SpringerLink
Log in

Characterization of Degradation Products and Drug–Excipient Interaction Products of Erdafitinib by LC–Q-TOF-MS/MS and NMR

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

Erdafitinib is a potent and selective tyrosine kinase receptor inhibitor used to treat advanced or metastatic urothelial carcinoma. The purpose of this study is to explore the degradation behavior of erdafitinib when exposed to various stress conditions as per ICH, along with its compatibility with various excipients under accelerated stability conditions. The degradation and interaction products formed under various conditions were separated using phenomenix Gemini C18 column (250 × 4.6 mm; 5 μm) with 10 mM ammonium acetate (pH 4.50) buffer and methanol as mobile phase in gradient elution mode at a flow rate of 1 mL/min. Erdafitinib was found to be labile in hydrolytic, photolytic and oxidative stress conditions. It was also found to be incompatible with polyethylene glycol-4000, polyvinyl pyrrolidone-K30, crospovidone and carboxymethylcellulose when exposed to accelerated stability conditions. A total of eight novel degradation products and one interaction product were generated. LC-Q TOF-MS/MS studies were conducted to propose the structures of degradation and interaction products formed by comparing with the fragmentation pattern of the drug. NMR study was also conducted to confirm the chemical structures of two degradation products (DP7 and DP8). Subsequently, the degradation pathway of erdafitinib was also laid down. Further, in silico toxicity and mutagenicity data was generated using DEREK and Sarah software. DP1, DP4, DP5, DP6, DP7 and DP9 show mutagenicity as endpoint.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The data that support the findings of this study is available in the manuscript as well as supporting information files. In addition, data can be available from the corresponding author upon reasonable request.

References

  1. Bharate SS (2021) Critical analysis of drug product recalls due to nitrosamine impurities. J Med Chem 64(6):2923–2936

    Article  CAS  PubMed  Google Scholar 

  2. Blessy M, Patel RD, Prajapati PN, Agrawal YJ (2014) Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal 4(3):159–165

    Article  CAS  PubMed  Google Scholar 

  3. Scheers E, Borgmans C, Keung C, Bohets H, Wynant I, Poggesi I, Cuyckens F, Leclercq L, Mamidi R (2021) Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Xenobiotica 51(2):177–193

    Article  CAS  PubMed  Google Scholar 

  4. Elawady T, Khedr A, Nahed EE, Belal F (2022) Study of erdafitinib stress degradation behavior using HPLC-UV analysis and multistage fragmentation ion trap mass spectrometry. Microchem J 179:107432

    Article  CAS  Google Scholar 

  5. Singh S, Bakshi M (2000) Guidance on the conduct of stress tests to determine inherent stability of drugs. Asian J Pharm 24–24

  6. ICH (2006) Stability testing of new drug substances and products Q1A(R2). International Council for Harmonisation, IFPMA, Geneva, Switzerland

  7. ICH (2005) Photostability testing of new drug substances and products Q1B. International Council for Harmonisation, IFPMA, Geneva, Switzerland

  8. Rowe RC, Sheskey P, Quinn M (2009) Handbook of pharmaceutical excipients. Libros Digitales-Pharmaceutical Press

  9. Kurmi M, Sahu A, Ladumor MK, Bansal AK, Singh S (2019) Stability behaviour of antiretroviral drugs and their combinations. 9: identification of incompatible excipients. J Pharm Biomed Anal 166:174–182

    Article  CAS  PubMed  Google Scholar 

  10. Dhiman V, Singh DK, Ladumor MK, Singh S (2017) Characterization of stress degradation products of amodiaquine dihydrochloride by liquid chromatography with high-resolution mass spectrometry and prediction of their properties by using ADMET Predictor™. J Sep Sci 40(23):4530–4540

    Article  CAS  PubMed  Google Scholar 

  11. Pravinchandra S, Kurmi M, Kumar S, Singh S (2015) Forced degradation of lafutidine and characterization of its non-volatile and volatile degradation products using LC-MS/TOF, LC-MS n and HS-GC-MS. NJC 39(12):9679–9692

    Article  CAS  Google Scholar 

  12. Velip L, Dhiman V, Kushwaha BS, Golla V, Gananadhamu S (2022) Identification and characterization of urapidil stress degradation products by LC-Q-TOF-MS and NMR: toxicity prediction of degradation products. J Pharm Biomed Anal 211:114612

    Article  CAS  PubMed  Google Scholar 

  13. Baertschi S (2005) Pharmaceutical stress testing-predicting drug degradation; special Indian edn. Taylor & Francis Group, New York

    Book  Google Scholar 

  14. Lecoeur M, Vérones V, Vaccher C, Bonte JP, Lebegue N, Goossens JF (2012) Structural elucidation of degradation products of a benzopyridooxathiazepine under stress conditions using electrospray orbitrap mass spectrometry—study of degradation kinetic. Eur J Pharm Sci 45(5):559–569

    Article  CAS  PubMed  Google Scholar 

  15. Liu S, Zhao Z, Wang Y (2019) Construction of N-heterocycles through cyclization of tertiary amines. Chem Eur J 25(10):2423–2441

    Article  CAS  PubMed  Google Scholar 

  16. Sahu A, Sengupta P (2020) Time of flight mass spectrometry based in vitro and in vivo metabolite profiling of ribociclib and their toxicity prediction. J Chromatogr B Biomed Appl 1147:122142

    Article  CAS  Google Scholar 

  17. Wang D, Luo L, Peng Y, Wang J, Liang J, Xu D, Feng H, Zeng L, Wang J (2020) Detection of two genotoxic impurities in drug substance and preparation of imatinib mesylate by LC–MS/MS. Chromatographia 83(7):821–828

    Article  CAS  Google Scholar 

  18. Shah RP, Sahu A, Singh S (2013) LC-MS/TOF, LC-MSn, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: a comprehensive approach during drug development. J Anal Bioanal Chem 405(10):3215–3231

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are very thankful to the National Institute of Pharmaceutical Education and Research [NIPER], Hyderabad, for providing the research facilities; Science and Engineering Research Board (SERB), Department of Science and Technology (DST), New Delhi, India for providing the research funding and fellowship to one of the authors Mr. Laximan Velip (SERB File no: EEQ/2018/001461).

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, 500037, India

    Laximan Velip, Vivek Dhiman, Bhoopendra Singh Kushwah & Gananadhamu Samanthula

Authors
  1. Laximan Velip
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivek Dhiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhoopendra Singh Kushwah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gananadhamu Samanthula
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Laximan Velip: conceptualization, methodology, investigation, formal analysis, data curation, writing—original draft, writing—review and editing. Vivek Dhiman: writing—original draft. Bhoopendra Singh Kushwah: writing—original draft. Gananadhamu Samanthula: conceptualization, methodology, writing—original draft, writing—review and editing, supervision.

Corresponding author

Correspondence to Gananadhamu Samanthula.

Ethics declarations

Conflict of Interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 3975 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Velip, L., Dhiman, V., Kushwah, B.S. et al. Characterization of Degradation Products and Drug–Excipient Interaction Products of Erdafitinib by LC–Q-TOF-MS/MS and NMR. Chromatographia 86, 627–638 (2023). https://doi.org/10.1007/s10337-023-04268-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-023-04268-x

Keywords

Search

Navigation